^
Association details:
Biomarker:TNFRSF1B overexpression
Cancer:Breast Cancer
Drug Class:Immunotherapy
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments

Published date:
02/14/2023
Excerpt:
Importantly, high expression of TNFR2 is associated with poor responses to the treatment with ICIs in BRCA, HCC, LUSC, and MELA. In conclusion, the expression of TNFR2 in TME may be a reliable biomarker for the precision of ICIs treatment of cancer patients, and this idea merits further research.
DOI:
10.3389/fimmu.2023.1097090